As Ozempic, Wegovy, Mounjaro and other injectable diabetes and weight-loss medications continue to make headlines for the successes and challenges many see with the medications for obesity and metabolic conditions, questions — regarding impacts on pregnant persons, potential uses for other medical conditions, concerns over counterfeit products that have flooded the market, discussions over what these mean for those with histories of disordered eating and more — continue to emerge. On Monday, March 18, 2024, experts from the University of Maryland, Baltimore (UMB) met with members of the press for a virtual press briefing to discuss these topics and more. UMB’s renowned experts from its Schools of Medicine, Pharmacy, and Social Work provided important updates and insights on various aspects of these medications and their impact on patients.This panel discussion includes:• Experts from University of Maryland Baltimore discuss various medications and their effects• Discussion on the limitations of previous weight loss medications and their side effects• Explanation of how GLP-1 agonists work to control blood glucose levels and decrease hunger• Emphasis on the importance of treating obesity as a chronic disease and the benefits of doing so